Birdshot Chorioretinopathy
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Old and New Challenges in Uveitis Associated with Behçet's Disease
Journal of Clinical Medicine Review Old and New Challenges in Uveitis Associated with Behçet’s Disease Julie Gueudry 1,* , Mathilde Leclercq 2, David Saadoun 3,4,5 and Bahram Bodaghi 6 1 Department of Ophthalmology, Hôpital Charles Nicolle, F-76000 Rouen, France 2 Department of Internal Medicine, Hôpital Charles Nicolle, F-76000 Rouen, France; [email protected] 3 Department of Internal Medicine and Clinical Immunology, AP-HP, Centre National de Références Maladies Autoimmunes et Systémiques Rares et Maladies Autoinflammatoires Rares, Groupe Hospitalier Pitié-Salpêtrière, F-75013 Paris, France; [email protected] 4 Sorbonne Universités, UPMC Univ Paris 06, INSERM, UMR S 959, Immunology-Immunopathology-Immunotherapy (I3), F-75005 Paris, France 5 Biotherapy (CIC-BTi), Hôpital Pitié-Salpêtrière, AP-HP, F-75651 Paris, France 6 Department of Ophthalmology, IHU FOReSIGHT, Sorbonne-AP-HP, Groupe Hospitalier Pitié-Salpêtrière, F-75013 Paris, France; [email protected] * Correspondence: [email protected]; Tel.: +33-2-32-88-80-57 Abstract: Behçet’s disease (BD) is a systemic vasculitis disease of unknown origin occurring in young people, which can be venous, arterial or both, classically occlusive. Ocular involvement is particularly frequent and severe; vascular occlusion secondary to retinal vasculitis may lead to rapid and severe loss of vision. Biologics have transformed the management of intraocular inflammation. However, the diagnosis of BD is still a major challenge. In the absence of a reliable biological marker, diagnosis is based on clinical diagnostic criteria and may be delayed after the appearance of the onset sign. However, therapeutic management of BD needs to be introduced early in order to control inflammation, to preserve visual function and to limit irreversible structural damage. -
The Uveo-Meningeal Syndromes
ORIGINAL ARTICLE The Uveo-Meningeal Syndromes Paul W. Brazis, MD,* Michael Stewart, MD,* and Andrew G. Lee, MD† main clinical features being a meningitis or meningoenceph- Background: The uveo-meningeal syndromes are a group of disorders that share involvement of the uvea, retina, and meninges. alitis associated with uveitis. The meningeal involvement is Review Summary: We review the clinical manifestations of uveitis often chronic and may cause cranial neuropathies, polyra- and describe the infectious, inflammatory, and neoplastic conditions diculopathies, and hydrocephalus. In this review we define associated with the uveo-meningeal syndrome. and describe the clinical manifestations of different types of Conclusions: Inflammatory or autoimmune diseases are probably uveitis and discuss the individual entities most often associ- the most common clinically recognized causes of true uveo-menin- ated with the uveo-meningeal syndrome. We review the geal syndromes. These entities often cause inflammation of various distinctive signs in specific causes for uveo-meningeal dis- tissues in the body, including ocular structures and the meninges (eg, ease and discuss our evaluation of these patients. Wegener granulomatosis, sarcoidosis, Behc¸et disease, Vogt-Koy- anagi-Harada syndrome, and acute posterior multifocal placoid pig- ment epitheliopathy). The association of an infectious uveitis with an acute or chronic meningoencephalitis is unusual but occasionally the eye examination may suggest an infectious etiology or even a The uveo-meningeal syndromes are a specific organism responsible for a meningeal syndrome. One should consider the diagnosis of primary ocular-CNS lymphoma in heterogeneous group of disorders that share patients 40 years of age or older with bilateral uveitis, especially involvement of the uvea, retina, and meninges. -
Approach to Intermediate Uveitis Kirti Jaisingh, Amit Khosla, Murthy Somasheila, Reema Bansal, Parthopratim Dutta Majumder, Padmamalini Mahendradas
Ophthalmic Deliberations Approach to Intermediate Uveitis Kirti Jaisingh, Amit Khosla, Murthy Somasheila, Reema Bansal, Parthopratim Dutta Majumder, Padmamalini Mahendradas The term “intermediate uveitis” describes inflammation of the anterior vitreous, ciliary body and peripheral retina Kirti Jaisingh MS, DNB, FICO which may or may not be associated with infection or Fellow, Vitreo-Retinal Surgery systemic disease. A subset of this, which is not associated Sir Ganga Ram Hospital with any systemic disease is termed as “pars planitis”.1 It Rajinder Nagar, Delhi, India comprises of approximately 9.5-17.4% of all uveitis.2,3 The prevalence of active intermediate uveitis in a South India- based study was 0.25%.3-5 Intermediate uveitis presents with minimal symptoms, commonly blurred vision and floaters.5-7 The characteristic Amit Khosla MS, DNB of this subtype of ocular inflammatory disease is a relapsing Senior Consultant, remitting nature of inflammation leading to chronicity, Uveitis and Vitreo-Retinal Services hence significant complications. Corticosteroids have been Sir Ganga Ram Hospital Rajinder Nagar, Delhi, India recommended as the first line of treatment. However, in a country known to be endemic for tuberculosis, steroids can only be given after ruling out tuberculosis with the aid of various investigations like Mantoux, Quantiferon Gold, chest X ray(CXR), Computerised tomography of chest (CECT), PCR from ocular fluids, etc. Improper treatment or early taper of drugs are often responsible for recurrences.8,10 Still, Somasheila Murthy MS, DOMS, FCP Head of Service, Corneal Diseases, there is no consensus regarding the end point of treatment. Tej Kohli Cornea Institute, Consultant, Although with the advent of immunosuppressives11-15, Uveitis Service,L.V.Prasad Eye Institute, complications due to long term steroid use have reduced Kallam Anji Reddy Campus, L.V.Prasad Marg, Banjara Hills, Hyderabad, India markedly, adequate management of intermediate uveitis is still lacking in multiple areas. -
UVEITIS Eye74 (1)
UVEITIS Eye74 (1) Uveitis Last updated: May 9, 2019 Classification .................................................................................................................................... 1 Etiologic categories .......................................................................................................................... 2 Treatment ......................................................................................................................................... 2 Complications ................................................................................................................................... 2 COMMON UVEITIC SYNDROMES ............................................................................................................. 2 Masquerade Syndromes ................................................................................................................... 3 UVEITIS - heterogenous ocular diseases - inflammation of any component of uveal tract (iris, ciliary body, choroid). CLASSIFICATION ANTERIOR UVEITIS (most common uveitis) - localized to anterior segment - iritis and iridocyclitis. IRITIS - white cells confined solely to anterior chamber. IRIDOCYCLITIS - cellular activity also involves retrolental vitreous. etiology (most do not have underlying systemic disease): 1) idiopathic postviral syndrome (most commonly 38-60%) 2) HLA-B27 syndromes, many arthritic syndromes (≈ 17%) 3) trauma (5.7%) 4) herpes simplex, herpes zoster disease (1.9-12.4%) 5) iatrogenic (postoperative). tends to -
Relapsing Polychondritis
Relapsing polychondritis Author: Professor Alexandros A. Drosos1 Creation Date: November 2001 Update: October 2004 Scientific Editor: Professor Haralampos M. Moutsopoulos 1Department of Internal Medicine, Section of Rheumatology, Medical School, University of Ioannina, 451 10 Ioannina, GREECE. [email protected] Abstract Keywords Disease name and synonyms Diagnostic criteria / Definition Differential diagnosis Prevalence Laboratory findings Prognosis Management Etiology Genetic findings Diagnostic methods Genetic counseling Unresolved questions References Abstract Relapsing polychondritis (RP) is a multisystem inflammatory disease of unknown etiology affecting the cartilage. It is characterized by recurrent episodes of inflammation affecting the cartilaginous structures, resulting in tissue damage and tissue destruction. All types of cartilage may be involved. Chondritis of auricular, nasal, tracheal cartilage predominates in this disease, suggesting response to tissue-specific antigens such as collagen II and cartilage matrix protein (matrillin-1). The patients present with a wide spectrum of clinical symptoms and signs that often raise major diagnostic dilemmas. In about one third of patients, RP is associated with vasculitis and autoimmune rheumatic diseases. The most commonly reported types of vasculitis range from isolated cutaneous leucocytoclastic vasculitis to systemic polyangiitis. Vessels of all sizes may be affected and large-vessel vasculitis is a well-recognized and potentially fatal complication. The second most commonly associated disorder is autoimmune rheumatic diseases mainly rheumatoid arthritis and systemic lupus erythematosus . Other disorders associated with RP are hematological malignant diseases, gastrointestinal disorders, endocrine diseases and others. Relapsing polychondritis is generally a progressive disease. The majority of the patients experience intermittent or fluctuant inflammatory manifestations. In Rochester (Minnesota), the estimated annual incidence rate was 3.5/million. -
Noninfectious Uveitis of the Posterior Segment Original Release: May 1, 2018 Expiration: May 31, 2019
CME Monograph global approaches for managing NoNINfEctIouS uVEItIS of thE PoStErIor SEGMENt Original Release: May 1, 2018 Expiration: May 31, 2019 Visit https://tinyurl.com/CMEUVEITIS for online testing and instant CME certificate. Faculty Quan Dong Nguyen Bahram Bodaghi Diana V. Do James P. Dunn Vishali Gupta MD, MSc (Chair) MD, PhD MD MD MD This continuing medical education activity is jointly provided by New York Eye and Ear Infirmary of Mount Sinai and MedEdicus LLC. This continuing medical education activity is supported through an unrestricted educational grant from Santen Pharmaceutical Co, Ltd. Distributed with LEARNING METHOD AND MEDIUM Diana V. Do, MD, and her partner/spouse had a financial This educational activity consists of a supplement and ten agreement or affiliation during the past year with the (10) study questions. The participant should, in order, read following commercial interests in the form of the learning objectives contained at the beginning of this Consultant/Advisory Board: Santen Pharmaceutical Co, Ltd; supplement, read the supplement, answer all questions in Contracted Research: Santen Pharmaceutical Co, Ltd. the post test, and complete the Activity Evaluation/Credit James P. Dunn, MD, had a financial agreement or affiliation Request form. To receive credit for this activity, please follow during the past year with the following commercial interests the instructions provided on the post test and Activity in the form of Consultant/Advisory Board: Santen Faculty Evaluation/Credit Request form. This educational activity Pharmaceutical Co, Ltd; Honoraria from promotional, should take a maximum of 1.5 hours to complete. advertising or non-CME services received directly from Quan Dong Nguyen, MD, MSc (Chair) CONTENT SOURCE commercial interest of their Agents (eg, Speakers Bureaus): Professor of Ophthalmology This continuing medical education (CME) activity captures AbbVie Inc. -
Evaluation of Fluocinolone Acetonide 0.19 Mg Intravitreal Implant in the Management of Birdshot Retinochoroiditis AUTH
TITLE: Evaluation of Fluocinolone Acetonide 0.19 mg Intravitreal Implant in the management of Birdshot Retinochoroiditis AUTHORS: Sofia Ajamil-Rodanes1, Ilaria Testi1, Joshua Luis1, Anthony G. Robson1, 2, Mark Westcott1, 2, Carlos Pavesio1, 2 Corresponding Author Sofia Ajamil-Rodanes Ophthalmology department Moorfields Eye Hospital NHS Foundation Trust 162 City Rd, Old Street, London EC1V 2PD [email protected] Full name, department, institution, city and country of all co-authors Testi, Ilaria;Ophthalmology, Moorfields Eye Hospital NHS Foundation Trust, London, UK Luis, Joshua; Ophthalmology, Moorfields Eye Hospital NHS Foundation Trust, London, UK. Robson, Anthony G; Electrophysiology department. Moorfields Eye Hospital, National Health Service Foundation Trust, London, United Kingdom. Institute of Ophthalmology, University College London, United Kingdom Pavesio, Carlos; Ophthalmology, Moorfields Eye Hospital NHS Foundation Trust, London, UK. Institute of Ophthalmology, University College London, United Kingdom Westcott, Mark; Ophthalmology, Moorfields Eye Hospital NHS Foundation Trust, London, UK. Institute of Ophthalmology, University College London, United Kingdom Word count, excluding title page, abstract, references, figures and tables 3393 words SYNOPSIS Retrospective study to examine therapeutic action of Iluvien® in retinal and choroidal inflammation in patients with birdshot retinochoroiditis. Our findings suggest retinal improvement but choroidal inflammation seems to persist. ABSTRACT Purpose: To report treatment outcomes -
Intermediate Uveitis
Intermediate Uveitis Vakur Pinar, MD Case Presentation A 32-year old woman presented with visual loss in her right eye on8/9/95. She was diagnosed with bilateral pars planitis with vitreoushemorrhage and inferior snowbank in the left eye in 1986. Subsequently she developed rhegmatogenous retinal detachment in that eye. Pars plana vitrecromy with endolaser panretinal photocoagulation (PRP) and scleral buckling OS was done. One year later she had cataract extraction with posterior chamber IOL implantation OS. Her right eye was treated with monthly periocular corticosteroid injections and peripheral cryotherapy. She was intolerant to Prednisone and discontinued Motrin after 2 months because "it didn't work". Review of systems revealed paresthesias in legs for the past 10 years, multiple allergies, arthritis, sinusitis, peptic ulcer and seizures since she had encephalitis in 1989. VA was 20/70 OD and counting fingers from 2 feet OS. Intraocular pressures were 19 mmHg OD, 9 mmHg OS. Slit lamp examination revealed normal anterior segment findings in the right eye; a few small,round white keratic precipitates (KPs) inferiorly, 2+ cells and 1+ flare in the anterior chamber OS. There was a large superior peripheral iridectomy OS. PC IOL was coated with inflammatory cells and there was a dense posterior capsule opacification. Fundus examination of the right eye revealed 1+ vitreous cells, cystoid macular edema, mild optic disc edema and peripapillary edema which were confirmed by fluorescein angiography (Figure1). Fig 1 There was a collagen band over the pars plana and pigmentary changes in the peripheral retina OD. There was no view due to hazy media in the left eye. -
Birdshot Chorioretinopathy: Clinical Characteristics and Evolution*
Br J Ophthalmol: first published as 10.1136/bjo.72.9.646 on 1 September 1988. Downloaded from British Journal of Ophthalmology, 1988, 72, 646-659 Birdshot chorioretinopathy: clinical characteristics and evolution* HILDE A PRIEM'2 AND JENDO A OOSTERHUIS2 From the 'Eye Clinic, University ofGent, Belgium, and the 2Eye Clinic, University ofLeiden, The Netherlands SUMMARY During the period 1980-6 102 patients from 14 European eye clinics were diagnosed as having birdshot chorioretinopathy (BSCR). All were Caucasian, and the series consisted of 47 men and 55 women, with a mean age of 52*5 years. The major findings in this rare disorder concern the ocular fundus. Most marked are the patterned distribution of depigmented spots without hyperpigmentation, radiation from the optic disc in association with vitritis, retinal vasculopathy with frequent cystoid macular oedema, and involvement of the optic nerve head. The distribution and appearance of the lesions suggest that they are related to the major choroidal veins. Complications of the disease were epiretinal membranes, retinal neovascularisation, recurrent vitreous haemorrhage, subretinal neovascular membranes occurring both in the juxtapapillary and macular regions, and optic atrophy. The medical history was not contributory. HLA testing showed very strong disease association with HLA A29 (95.8%). The evidence suggests that it is a single disease a entity rather than group of disorders because of the remarkable similarity in the copyright. ophthalmological appearance and the clinical course, combined with the exceptionally high association with HLA A29. In 1980 a rare ocular disease was described by Ryan and Maumenee.' In the absence of a known aetiology, they chose the descriptive name 'birdshot http://bjo.bmj.com/ retinochoroidopathy' inspired by the unusual picture, which showed multiple small, cream coloured lesions, scattered mainly around the optic disc and radiating towards the equator, without hyperpigmentation at the level of the retinal pigment _ * epithelium. -
Relapsing Polychondritis Jozef Rovenský1* and Marie Sedláčková2
Rovenský et al. J Rheum Dis Treat 2016, 2:043 Volume 2 | Issue 4 Journal of ISSN: 2469-5726 Rheumatic Diseases and Treatment Review Article: Open Access Relapsing Polychondritis Jozef Rovenský1* and Marie Sedláčková2 1National Institute of Rheumatic Diseases, Piešťany, Slovak Republic 2Department of Rheumatology and Rehabilitation, Thomayer Hospital, Prague 4, Czech Republic *Corresponding author: Jozef Rovenský, National Institute of Rheumatic Diseases, Piešťany, Slovak Republic, E-mail: [email protected] of patients; in the systemic vasculitis subgroup survival is similar to Abstract that of patients with polyarteritis (up to about five years in 45% of Relapsing polychondritis (RP) is a rare immune-mediated disease patients). The period of survival is reduced mainly due to infection that may affect multiple organs. It is characterised by recurrent and respiratory compromise. episodes of inflammation of cartilaginous structures and other connective tissues, rich in glycosaminoglycan. Clinical symptoms Etiology and Pathogenesis concentrate in auricles, nose, larynx, upper airways, joints, heart, blood vessels, inner ear, cornea and sclera. The most prominent RP manifestation is inflammation of cartilaginous structures resulting in their destruction and fibrosis. Diagnosis of the disease is based on the Minnesota diagnostic criteria of 1986 and RP has to be suspected when the inflammatory It is characterised by a dense inflammatory infiltrate, composed bouts involve at least two of the typical sites - auricular, nasal, of neutrophil leukocytes, lymphocytes, macrophages and plasma laryngo-tracheal or one of the typical sites and two other - ocular, cells. At the onset, the disease affects only the perichondral area, statoacoustic disturbances (hearing loss and/or vertigo) and the inflammatory process gradually leads to loss of proteoglycans, arthritis. -
Intermediate Uveitis
Ocular Inflammation Service, Oxford Eye Hospital Intermediate Uveitis Information for patients, parents and carers page 2 What is intermediate uveitis? Uveitis is an inflammation of the inside of the eye, specifically the layer of the eye called the uvea. The term, ‘intermediate uveitis’ is used to describe the location of the inflammation in the eye. The part of the eye affected is the peripheral part (outer edge) of the retina (inner most layer of the eye), the vitreous and the pars plana. The part of the eye affected in intermediate uveitis. Retina Pars plana Vitreous Cornea Macula Lens Fovea Iris Optic nerve Uvea area affected by intermediate uvelitis The older terms ‘pars planitis’ and ‘cyclitis’ are often used to describe intermediate uveitis. Intermediate uveitis most commonly affects teenagers, but can also occur in very young children. page 3 Symptoms This is generally not a painful condition and your eyes are not likely to be red or sore. You are likely to have blurred vision and/or floaters (black dots or wispy lines that move across your field of vision). Both of your eyes are likely to be affected but not always at the same time and not to the same degree. You may have this condition for quite some time before it is diagnosed, because you might not have been aware of any problem. The severity of the condition varies greatly. Often vision may not be affected at all but complications such as vitreous opacification and macular oedema may cause vision loss (see next section for details). Some people with intermediate uveitis also develop anterior uveitis (also known as iritis). -
Melanocortin in the Pathogenesis of Inflammatory Eye Diseases
CME Monograph IL-6 ROS IL-6 ROS IL-6 ROS IL-12 TNFα IL-6 IL-12 TNFα IL-12 ROSTNF α IL-12 TNFα Melanocortin in the Pathogenesis of Infl ammatory Eye Diseases: Considerations for Treatment Visit https://tinyurl.com/melanocortin for online testing and instant CME certifi cate. ORIGINAL RELEASE: November 1, 2018 EXPIRATION: November 30, 2019 FACULTY QUAN DONG NGUYEN, MD, MSc (CHAIR) FRANCIS S. MAH, MD ROBERT P. BAUGHMAN, MD ROBERT C. SERGOTT, MD DAVID S. CHU, MD ANDREW W. TAYLOR, PhD This continuing medical education activity is supported through an unrestricted educational grant from Mallinckrodt. This continuing medical education activity is jointly provided by New York Eye and Ear Infi rmary of Mount Sinai and MedEdicus LLC. Distributed with LEARNING METHOD AND MEDIUM David S. Chu, MD, had a fi nancial agreement or affi liation during the past This educational activity consists of a supplement and six (6) study questions. year with the following commercial interests in the form of Consultant/Advisory The participant should, in order, read the learning objectives contained at the Board: AbbVie Inc; Aldeyra Therapeutics; Allakos Inc; Mallinckrodt; and Santen beginning of this supplement, read the supplement, answer all questions in the Pharmaceutical Co, Ltd; Contracted Research: Aldeyra Therapeutics; Allakos, Inc; post test, and complete the Activity Evaluation/Credit Request form. To receive Gilead; and Mallinckrodt; Honoraria from promotional, advertising or non-CME services received directly from commercial interest or their Agents (e.g., Speakers’ credit for this activity, please follow the instructions provided on the post test and Bureaus): AbbVie Inc; and Novartis Pharmaceuticals Corporation.